Universal reference book for medicines
Product name: CEREPRO (CEREPRO)

Active substance: choline alfoscerate

Type: Nootropic drug.
Holinomimetics of central action
Manufacturer: VEROPHARM (Russia)
Composition, form of production and packaging
soft gelatinous, from red to brown, oblong;
the contents of the capsules are oily, clear, colorless or slightly colored liquid.
1 caps.

choline alfoscerate (glycerylphosphoryl choline hydrate) 400 mg

Excipients: glycerol (glycerin), purified water.

The composition of the capsule shell: gelatin medical, glycerol (glycerin), methylparahydroxybenzoate (methylparaben), propyl parahydroxybenzoate (propylparaben), iron dye red oxide, titanium dioxide, purified water, sorbitol (sorbitol).

14 pcs.
- blisters (1) - packs of cardboard.

The product description was approved by the manufacturer for the 2009 print edition.


Holinomimetics of central action, which contains 40.5% of metabolically protected choline (metabolic protection contributes to the release of choline in the brain).Upon ingestion, it is cleaved under the action of enzymes on choline and glycerophosphate: choline participates in the biosynthesis of acetylcholine, one of the main neurotransmitter mediators;
glycerophosphate is a precursor of phospholipids (phosphatidylcholine) neuronal membrane. The drug provides the synthesis of acetylcholine and phosphatidylcholine in neuronal membranes, improves blood flow and enhances metabolic processes in the central nervous system, activates the reticular formation; increases the linear velocity of blood flow on the side of traumatic brain injury, contributes to the normalization of spatiotemporal characteristics of spontaneous bioelectrical activity of the brain; has a positive effect on the cognitive and behavioral responses of patients with cerebral vascular diseases.
The drug improves brain function, affecting the pathogenetic factors of the involutionary psychoorganic syndrome, changes the phospholipid composition of neuronal membranes and reduces cholinergic activity.
Dosolependently stimulates the release of acetylcholine, participating in the synthesis of phosphatidylcholine (membrane phospholipid), improves synaptic transmission, plasticity of neuronal membranes, receptor function.

Suction and distribution

After ingestion, absorption is 88%.

Easily penetrates the BBB, the concentration in the brain reaches 45% of the level in the blood plasma.

Metabolism and excretion

In the organism of choline, alphoscerate under the action of enzymes is biotransformed to choline and glycerophosphate (providing pharmacological effects of the drug).
85% is excreted by light in the form of carbon dioxide; The remaining part (15%) is excreted in urine and feces.

- acute and recovery periods of severe craniocerebral trauma and ischemic stroke, the recovery period of hemorrhagic stroke, with focal hemispheric symptoms or symptoms of brain stem damage;

- psycho-organic syndrome in the background of degenerative and involuntary changes in the brain;

- chronic insufficiency of cerebral circulation;

- Cognitive impairment (impaired mental function, memory, confusion, disorientation, decreased motivation, initiative and ability to concentrate), incl.
with dementia and encephalopathy;
- senile pseudo-melancholy.


In acute conditions, the drug is given in / m or / in (slowly) in a daily dose of 1 g (1 ampoule) for 10-15 days, then go on oral intake of the drug in a daily dose of 1.2 g (800 mg / 2 caps. / in the morning and 400 mg / 1 caps. / day) for 6 months.

In chronic conditions, the drug is administered orally 400 mg (1 caps.) 3 times / day.
The duration of therapy is 3-6 months.
Capsules are recommended to be taken before meals.


From the side of the digestive system: nausea (as a consequence of dopaminergic activation).

Other: allergic reactions.


- Pregnancy;

- the period of lactation (breastfeeding);

- Hypersensitivity to the components of the drug.


The drug is contraindicated for use in pregnancy and lactation (breastfeeding).

In experimental studies, there was no mutagenic and teratogenic effect of the drug, as well as an effect on reproductive functions.


If there is nausea after taking the drug should reduce the dose.

Impact on the ability to drive vehicles and manage mechanisms

Cerepro does not affect the speed of psychomotor reactions.


Symptoms: indigestion.

Treatment: gastric lavage, reception of activated charcoal, symptomatic therapy.


The drug interaction of Cerepro is not established.


The drug is released by prescription.


List B. The drug should be stored in a dry, protected from light and out of reach of children at a temperature of no higher than 25 ° C.
Shelf life - 2 years.
Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y
Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!